INTRODUCTION
The Sleep Heart Health Study (SHHS) has examined the cross sectional association between sleep-disordered breathing and self reported cardiovascular disease (CVD) and the multivariable-adjusted relative odds (95% CI) of prevalent (self reported) CVD were 1.42 (1.13-1.78) for the fourth quartiles 1 . Sleep-disordered breathing was associated more strongly with self reported heart failure (2.38), stroke (1.58), than with self reported CVD. The SHHS has shown, that in a group of patients free of self reported CVD in the begin of the study moderate levels of sleep-disordered breathing were common with a median Respiratory Disturbance Index (RDI) of 4.0. The risk for CVD events increased in future follow-up 2 . Mooe et al. 3 concluded in the study of 408 patients with CVD, that sleep-disordered breathing is associated with a worse longterm prognosis and has an independent association with cerebrovascular events. In a recent study Gottlieb et al. 4 presented, that OSA was a significant predictor of incident coronary heart disease in men ≤70 years of age. Among men 40-70 years old, those with AHI≥30 were 68% more likely to develop coronary heart disease than those with AHI <5.
CASE PRESENTATION
A 54-year-old Caucasian man was admitted on 29 th March 2007 to the cardiology clinic due to serious chest pain. Vertebrogenic pain syndrome, hepatitis B in 1977 (he is HBsAg positive) and surgery for Achilles tendon were mentioned in the patient's medical history. He is a lifelong non-smoker. He was evaluated in a sleep laboratory several years ago where an obstructive sleep apnea was diagnosed. He was not treated or observed. Family history: mother died age 40 as a result of a rheumatic mitral valve disease; father died age 80 due to liver carcinoma; sister and children are healthy. Medication: silymarin.
Physical examination (PE): blood pressure (BP) 150/80, heart rate (HR) 82, weight 97 kg, height 187 cm, body mass index 27.7 and no other abnormalities.
Electrocardiogram: sinus rhythm, straightened ST I, II, V 5, 6, depression ST V 1-3.
Laboratory results: normal potassium, sodium, chlorides, alanine amino transferase, aspartate amino transferase, gamma glutamyl transferase, glycaemia, total cholesterol, high-density lipoprotein (HDL), triglycerides, low-density lipoprotein (LDL). Out of range: creatine kinase (CK) 3.57 μ k at/l, CK/CK Mb 14% (norm.<6%), troponin T 0.08 μg/l (norm. 0.03), bilirubin 38 μmol/l.
A coronarography was carried out and this revealed the following: occluded ramus diagonalis (RD1), 95% ostial stenosis (RD2), 99% critical stenosis ramus circumflexus (RCX) (Fig. 1) , arteria coronaria dextra (ACD) without stenosis. Percutaneous coronary intervention (PCI]) was performed on RD1 with a stent coroflex 3.0 x 13 mm, (TIMI flow 3), PCI on RCX with a stent coroflex 3.0 x 13 mm (a small residue of stenosis up to 15%).
The patient was discharged in good health on 4 th April 2007. His medication included beta blocker (metoprolol), clopidogrel, aspirin, ACE inhibitor (ramipril), statin (atorvastatin), silymarin.
He The patient underwent single-photon-emission computed tomography (SPECT) on June 2007 which showed hypokinesis laterally and inferoapically, the resting EF was 45%, the defect was reversible and assessed as medially severe ischemia (Fig. 2) . Complicated course of ischemic heart disease in a patient with obstructive sleep apnea A control hospitalization at the cardiology department took place on 12 th June 2007, PE values at admission were: BP 130/90, HR 76, laboratory values were within normal levels, total cholesterol 2.44 mmol/l, triglycerides 1.56 mmol/l, HDL 0.98 mmol/l, LDL 0.76 mmol/l. The patient subsequently underwent a coronarography, where in stent restenosis 90% of RD1, stenosis 90% of RD2, in stent restenosis 90% of RCX were found (Fig. 3) . All of these findings were managed by a balloon angioplasty. The patient has not reported any significant complaint after this hospitalization. He has remained on the same pharmacological therapy till now (last visit November 2010).
DISCUSSION
We present a patient with an acute myocardial infarction who was without any classic coronary artery disease risk factors [non-smoker, normal blood pressure, normal total and low-density lipoprotein cholesterol levels, borderline high-density lipoprotein cholesterol level, with good physical activity, without diabetes, without abdominal obesity, a negative family history]. The only risk factor which was present in the patient was untreated OSA.
As a number of studies have revealed that the incidence of OSA in patients with myocardial infarction (MI) is likely to be high. Lee et al. 5 found that in a group of 120 patients with acute MI, 65,7% has OSA with AHI>15. In these patients diabetes mellitus was a risk factor for OSA (OR 2.86).
OSA can also figure as a risk factor for MI. The diurnal variation of progression is different in patients with or without OSA. Kuniyoshi et al. 6 reported that in patients with an onset of MI from midnight to 6 am, up to 91% of patients had OSA and the risk of developing MI was six times higher than during the rest of the day. Difficulties also occurred in our patients around 3 am.
OSA can activate pathological routes which can lead to insulin resistance, development of atherosclerosis and hypertension 7 . The combination of hypertension and OSA has an additive effect on the development of atherosclerosis. The Intima-media index has a positive correlation with the systolic blood pressure and the AHI index 8 . Systemic inflammation, sympathetic activation, the effect of high blood pressure and oxidative stress, can all lead to the development of the endothelial dysfunction in patients with OSA 9 . Endothelial dysfunction leads to an increase in the risk of cardiovascular disease, a decrease in endothelial NO and increase in oxidative stress in patients with OSA 10 . Certain cytokines (e.g. TNF-α) can participate in the . Although classical risk factors were absent in the case of the patient described, the findings of advanced atherosclerosis were substantial, with significant progressions in the period without adequate treatment for OSA.
A potential mechanism for the development of acute MI in our patient could have been higher trombocyte agregability of thrombocytes, which has been described in patients with OSA 12 .
The clinical status of our patient had not been stabilized over maximal cardiological treatment until one year of adequate use of CPAP. The improved prognosis of patients with heart disease after CPAP treatment has been described by several authors.
Buchner et al. 13 for example, showed that CPAP treatment of patients with OSA had reduced risk of cardiovascular event (non-fatal MI, acute coronary syndrome with revascularization, death because of MI ) by 64% in a group of 449 patients independent of age and coincident co-morbidities. In a similar fashion, Marin et al. 14 described an increase in fatal events (OD 2.87) and nonfatal events in patients with untreated OSA. In the same manner, Doherty et al. 15 have confirmed reduced cardiovascular mortality in patients with treated OSA in comparison with the control group. CPAP treatment leads to a decrease in thrombocyte activation and this may explain the stabilization of the health status of our patient following long-term use of the CPAP device 16 . Cassar et al. 17 showed that patients with OSA who are treated with CPAP have a lower incidence of post PCI cardiac death in comparison with patients without treatment.
One year of continuous positive airway pressure treatment was needed to stabilize health condition of our patient, which is now stable for up two years.
CONCLUSION
Given the complicated course of ischemic heart disease in patients with OSA, we believe that OSA diagnosis would be advisable each time these patients with symptoms of myocardial infarction, ischemic heart disease and OSA are examined. Even more important, however, is proper treatment of the OSA when it is present.
